【摘要】 目的 :研究吉西他滨 (健择 )联合顺铂治疗晚期肝癌的疗效、不良反应及疾病相关症状的改善。方法 :吉西他滨 1 0 0 0～ 1 2 50mg m2 ,平均使用剂量 1 1 2 0mg m2 ,静脉滴注 30分钟 ,第 1 ,8天 ,顺铂 2 5mg m2 ,静脉滴注 ,第1～ 3天 ,2 1天为 1周期 ,至少完成 2周期评价。结果 :1 6例患者中无CR患者 ,PR 4例 (2 5 % ) ,MR 6例 (37 5 % ) ,SD4例 (2 5 % ) ,PD 2例 (1 2 .5 % ) ,总有效率 2 5 % ,临床获益患者 (CR +PR +MR +SD) 1 4例 ,占 87.5 %。疾病相关症状改善 (DRSI) :1、2周期化疗结束后分别为 31 .3 % (5 1 6)和 68.8% (1 1 1 6)。主要不良反应为血液毒性 ,Ⅲ～Ⅳ级骨髓抑制发生率中白细胞减少占周期数的 1 5 .4% ,血红蛋白减少占 1 2 .8% ,血小板减少占 2 5 .6 % ;血小板最低值中位时间为化疗第 1 5天 ,不行任何治疗中位恢复时间为 1 0天 ,无血小板减少相关的并发症发生。非血液毒性轻微。结论 :吉西他滨联合顺铂治疗晚期肝癌具有较好的客观有效率 ,毒副反应能耐受 ,尤其是疾病相关症状改善率高 ,提高了患者的生存质量更多还原

【Abstract】 Purpose:To study the response rate and adverse reactions of gemcitabine and cisplatin in the treatment of advanced liver cancer and the disease related symptoms improvement(DRSI). Methods:16 patients of advanced liver cancer were treated from Dec. 1999 to Dec. 2001.Gemcitabine was used intravenously by infusion for 30 min with the dose from 1 000 mg/m 2 to 1 250 mg/m 2 on day 1,8,cisplatin was infused intravenously with a dose of 25 mg/m 2 on day 1,2,3.Twenty one days were counted as one cycle. After 2 cycles of the treatment the response rate and adverse reaction and clinical symptoms were evaluated. Results:Among these 16 patients,there was no complete response,PR 4(25%),MR 6(37.5%),SD 4(25%),PD 2(12.5%),and clinical benefit response(CR+PR+MR+SD)14(87.5%). DRSI could be observed in 31.3%(5/16) for 1 cycle and 68.8%(11/16) for 2 cycles.The main adverse reactions were hematologic toxicity(grade 3/4),which included leucopenia 15.4%(6/39),anemia 12.8%(5/39),thrombocytopenia 25.6%(10/39),and nonhematologic toxicity was mild.Conclusions:Combination of gemcitabine with cisplatin was an effective and new chemotherapy for advanced liver cancer,it has high DRSI and mild adverse reactions.更多还原